Tango therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Boston--(business wire)--tango therapeutics, inc. (nasdaq: tngx), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective december 2, 2024, the compensation committee of tango therapeutics' board of directors granted a non-qualified stock option to purchase 187,500 shares of its common stock and 31,250 restricted stock units (rsus) to a new employee under tango therapeutics' 2023 inducement.
NDAQ Ratings Summary
NDAQ Quant Ranking